FTD-TPI plus bevacizumab found to increase survival in refractory advanced CRC
Treatment with trifluridine-tipiracil (FTD-TPI) plus bevacizumab yields longer overall survival than FTD-TPI alone among patients with refractory metastatic colorectal cancer, according to a study published in the May 4 issue ...
May 4, 2023
0
2